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Hemorrhagic diathesis 62:S-87
Hemostasis 1180
Henoch Schönlein purpura 272
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Recirculation 1154
Recombinant human erythropoietin 1390
Recombinant proteinase 3 277
Recurrent idiopathic calcium renal stone 1429
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Renal allograft 1157, 1158
Renal allograft rejection 1131, 1429
Renal allografts 1132, 1159
Renal arteriography 569
Renal artery stenosis 273, 565, 569, 570, 1133, 1136, 1137
Renal Association 1129
Renal Association standards 1118, 1129
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Renal blood flow 1364
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Renal functional 1430
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Renal hemodynamics 63:S-185
Renal inflammation 572
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Renal interstitial fibroblasts 1497
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Renal replacement therapy 280, 1130, 1146, 1423
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Renal survival 61:S-71
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Risk factors for ESRD 63:S-l0
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Schiff base 79, 62:S-65
Sclerosis 63:S-191
Secondary hyperparathyroidism 1149, 1232
Serum albumin 577, 1120
Serum hemoglobin 577
Serum lipids 1132
Serum oxalate assay 1700
Serum potassium 1120
Sexual performance 1160
Sickle cell disease 565, 566
Signal transduction 60:S-66
Sinoaortic denervation 61:S-22
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T cell activation 273
T-cell adhesion 276
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T-cell receptor 563
Tcells 1125, 1439, 1678
T cell-specific chemokines 1521
TCV-116 3:S-208, 63:S-232
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TGFP 572, 63:S-239
TGF-f31 262, 276, 63:S-1l1
Thiazides 1137
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Unilateral ureteral obstruction 63:S-232
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Vesicoureteric reflux 1124, 1125
Viral vector 60:S-86
Vitamin B6 62:S-56
Vitamin D 39, 45, 62:S-60, 62:S-65, 62:S-69
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